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MHCclass I peptide complexes (pMHC) are rou-
tinely used to enumerate T cell populations and
are currently being evaluated as vaccines to
tumors and specific pathogens. Herein, we de-
scribe the structures of three generations of sin-
gle-chain pMHC progressively designed for the
optimal presentation of covalently associated
epitopes. Our ultimate design employs a versa-
tile disulfide trap between an invariantMHC res-
idue and a short C-terminal peptide extension.
This general strategy is nondisruptive of native
pMHCconformation andTcell receptor engage-
ment. Indeed, cell-surface-expressed MHC
complexes with disulfide-trapped epitopes are
refractory to peptide exchange, suggesting
they will make safe and effective vaccines. Fur-
thermore, we find that disulfide-trap stabilized,
recombinant pMHC reagents reliably detect
polyclonal CD8 T cell populations as proficiently
as conventional reagents and are thus well
suited to monitor or modulate immune re-
sponses during pathogenesis.
INTRODUCTION
Class I major histocompatibility complex (MHC) proteins
serve a critical role in the adaptive immune response by
binding short peptide fragments intracellularly and pre-
senting them at the cell surface for surveillance by cyto-
toxic T lymphocytes (CTLs). Structural studies of human
and murine MHC class I proteins have revealed that pep-
tides of eight to ten residues in length are presented to T
cell receptors (TCRs) in the context of a narrow groove
formed by two antiparallel a helices positioned above an
eight-strand, antiparallel b sheet [1–5]. This peptide-bind-
ing platform is comprised of the a1 and a2 domains of
a polymorphic heavy chain (HC), which also contains an
immunoglobulin-like a3 domain, a transmembrane seg-
ment, and a short cytoplasmic tail. Stable surface expres-
sion of MHC complexes requires the association of theChemistry & Biology 14, 9peptide-HC assembly with b2-microglobulin (b2m), which
contacts the a3 domain and supports the peptide-binding
platform.
The generation of antigen-MHC complexes for priming
and activating of specific CD8 T cell responses has been
the goal of a number DNA vaccination strategies [6]. In
some of these vaccination regimens, the immunogen is
encoded by a DNA delivery vector and is expressed in
vivo by transfected dendritic cells (DC) upon vaccination
[7]. The potency of such DNA vaccines is critically depen-
dent on the presentation of processed antigenic epitopes
by MHC class I on the surface of the transfected DCs.
However, certain immunologically important tumor- or
pathogen-derived antigens are not presented efficiently
at the plasma membrane. This inefficiency results from
the fact that the surface expression of pMHC is influenced
by a variety of factors including efficiency of antigen pro-
cessing [8, 9], specificity of peptide translocation into
the ER [10], interference by viral pathogens [11], and the
biogenesis and kinetic stability of the pMHC itself [12].
In addition to vaccine development, MHC proteins have
been used extensively to construct soluble multimer re-
agents that have been successfully used for T cell enu-
meration and diagnostics [13–18] and more recently for
the isolation of therapeutic antigen-specific T cells [19,
20]. A major challenge for the production and use of
pMHC multimers is peptide dissociation. Indeed, it has
been shown that naive CD8 T cells can activate each other
by cross presentation of dissociated peptide from soluble
recombinant pMHC [21]. This problem is especially rele-
vant to potential clinical applications of pMHC reagents
infused into patients for the manipulation of immune re-
sponses. These include, for example, antibody-mediated
targeting of MHC class I complexes to the surface of tu-
mor cells [22, 23] and direct in vivo modulation of T cells
by recombinant pMHC [24, 25].
Therefore, to enhance antigenic peptide presentation
and to prevent epitope dissociation from the MHC, we en-
gineered the pMHC as a covalent assembly. These engi-
neered proteins, which we term single-chain trimers
(SCTs), consist of a single polypeptide comprised of an
antigenic peptide followed by a flexible linker that con-
nects the C terminus of the peptide to the N terminus of
b2m and another flexible linker that connects the C09–922, August 2007 ª2007 Elsevier Ltd All rights reserved 909
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studies, we used the Kb-Ova complex as a platform to
create the first SCT. These studies revealed that SCT
transfected into cells assembled rapidly in the ER, ex-
hibited extended cell surface half-life, and were more re-
sistant to exogenous peptide exchange compared to Kb
loaded with endogenous peptides [26]. This first genera-
tion SCT, with its high-affinity Ova constituent, has been
particularly valuable in notable studies of the biology of
MHC class I [27, 28].
Upon further characterization, we found that extremely
high concentrations of competitor peptide could displace
the Ova sequence more easily in the SCT than in native
Kb-Ova [29]. This observation suggested that the pep-
tide-b2m linker was disrupting optimal anchoring of the
Ova C terminus. If this were true, the extended cell-surface
half-life of SCTs relative to native Kb-Ova likely reflects
their capacity to rebind the spacer-attached Ova rather
than continuous groove occupancy. Consequently, a sec-
ond SCT generation was designed to open the C-terminal
end of the MHC groove to better accommodate the
C-terminal linker of the presented peptide [29]. Our goal
was to optimize the SCT design for therapeutic and diag-
nostics applications, particularly when the incorporated
class I ligand was not of high affinity. With this in mind we
crystallized and solved the structures of the first and sec-
ond SCT generations in order to define the chemical basis
of peptide binding and presentation by these constructs.
Our structural data presented here show that we have suc-
cessfully re-engineered the SCT groove to accommodate
the free extrusion of the C-terminal peptide linker.
Improving upon these original constructs, we engi-
neered a third generation SCT by incorporating a disulfide
trap in the region of the SCT groove involved in binding the
C terminus of the peptide known as the F pocket of the
MHC. We reasoned that introduction of a disulfide trap
would lock in the linker-attached peptide and further stabi-
lize the integrity of the SCT. Herein, we present structural,
chemical, and functional characterizations of this new
construct and provide unequivocal evidence that the intro-
duction of an F pocket disulfide improves C-terminal
peptide anchoring, reliably precludes the binding of com-
petitive peptides, and preserves TCR engagement. Alto-
gether, these results suggested that an analogous disul-
fide bond could lock pMHC without the use of subunit
linkers. Indeed, we demonstrate here the use of such a di-
sulfide to trap a synthetic peptide in the groove of a soluble,
recombinant HC. We also show that tetramers con-
structed with disulfide-trapped pMHC (dt-pMHC) reliably
detect pathogen-specific T cells. The diagnostic, vaccine,
and immune regulatory applications of these various
pMHC designs are discussed.
RESULTS
Crystal Structure Analysis of a Single-Chain
pMHC Trimer
The first generation SCT, designated here SCTWT, was de-
signed by linking the C terminus of Ova (SIINFEKL, Oval-910 Chemistry & Biology 14, 909–922, August 2007 ª2007 Elsbumin, residues 257–264) by using a (Gly4-Ser)3 linker to
the N terminus of b2m and linking the C terminus of b2m
to the N terminus of the Kb HC using a (Gly4-Ser)4 linker
(Figure 1A). To probe the molecular means by which
MHC proteins designed as single-chain trimers bind and
present peptides and to obtain a structural framework
for their improvement, we initiated a crystallographic
investigation. Bacterially expressed and oxidatively re-
folded SCTWT protein crystallized in the primitive mono-
clinic space group P21 with two molecules per asymmetric
unit (Table 1). After initial refinement, interpretable electron
density was seen for the Ova peptide and linker residues
immediately C-terminal to Ova. The final electron density
map was of excellent quality with no ambiguities observed
for main-chain or side-chain atoms of the Ova peptide. In-
terpretable density was also observed for the entire pep-
tide-b2m linker. In contrast, no electron density was ob-
served for the b2m-HC linker or for residues 278–280 at
the C terminus of the HC. The final SCTWT model refined
to 2.0 A˚ resolution and has an R factor of 21.5% (Rfree
25.3%) with excellent geometry.
Our structural data reveals that the Ova portion of the
single chain is bound in the MHC groove in canonical fash-
ion (Figure 1B). The anchoring residues IleP2, PheP5, and
LeuP8 are buried in the complex and point toward the
b sheet platform in manner similar to that observed in
the native complex (Figures 2A and 2B) [30]. The pep-
tide-b2m linker extrudes from the C-terminal end of the
peptide-binding groove, traverses over the C-terminal,
TCR-proximal surface of the a1 helix, and joins the N ter-
minus of b2m on the membrane-proximal side of the pep-
tide-binding platform (Figure 1B, see also Figures 2B and
3B). This linker does not adopt any regular secondary
structure and is seen in different conformations in each
complex of the asymmetric unit consistent with its solvent
exposure (Figure 1B).
Structure-Based Design of Novel SCTs
A closer inspection of the SCTWT F pocket (Figure 2B) re-
veals that Tyr84 precludes optimal linker positioning by
forcing a near 90 turn in the protein main chain at the first
linker residue. Moreover, the closed nature of the SCT
groove constrained the linker extrusion over a conserved
TCR antigen recognition region [31, 32]. In order to improve
linker accommodation and to potentially enhance peptide-
MHC association, we re-engineered the peptide-binding
groove of the SCTWT protein. Our design was based on ex-
amination of MHC class I and class II structures, since
class II molecules allow binding of peptides with C-termi-
nal extensions [30, 33]. These comparisons revealed that
the invariant Tyr84 in class I proteins is prominent in closing
the MHC groove around the peptide C terminus.
Accordingly, we mutated Tyr84 to an Ala to create
SCTY84A (Figure 1A). Initial studies of immune recognition
of this SCT were highly suggestive that this mutation al-
lows relaxation of the peptide-b2m linker [34]. Next, we in-
troduced a stabilizing disulfide trap between the peptide
and the MHC by engineering a disulfide bond between
a cysteine introduced in place of Tyr84 and a cysteineevier Ltd All rights reserved
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and Structural Features
(A) Schematic representations of the SCTs are
shown. Ova, b2m, and HC are represented as
yellow, magenta, and cyan boxes, respec-
tively. The linkers (peptide-b2m linker, PBL,
and b2m-heavy-chain linker, BHL) are repre-
sented as thin orange boxes. Linker sequences
and residue numbering for Ova, b2m, and HC
are shown above their respective representa-
tions. Disulfide bonds bridging the indicated
cysteine residues are represented as green
brackets.
(B) Ribbon diagram of SCTWT. Ova and PBL are
rendered as ball-and-stick models and colored
as follows: Ova and PBL carbon atoms, yellow
and orange, respectively; nitrogen atoms, blue;
oxygen atoms, red. The protein is oriented with
the Ova N terminus on the left and the mem-
brane-proximal a3 domain at the bottom. A
possible conformation for BHL is represented
and rendered as small orange balls.
(C) Stereo representation of the experimental
electron density for the disulfide bond between
CysPBL2 and Cys84 in the dt-SCT and the sur-
rounding region. A simulated-annealing, omit
map (CNS) calculated at 1.80 A˚ is shown in
cyan at a contour of 2.0s. The FOFC map
was constructed from model phases calcu-
lated without the coordinates for Ova, PBL,
and residues 76 through 87 and 137 through
148 of one of the molecules in the asymmetric
unit. A ball-and-stick representation of the
omitted region of dt-SCT is shown and super-
posed onto the electron density and colored
as in (A) with sulfur atoms colored green.introduced at the second position in the peptide-b2m
linker (Figure 1A). We hypothesized that a Cys at position
84 would maintain an opening in the MHC groove and that
a disulfide bond at this position would re-establish
C-terminal anchoring. This SCT construct was designated
dt-SCT (disulfide-trapped SCT).Chemistry & Biology 14, 9We crystallized and solved the structures of SCTY84A
and dt-SCT. These proteins crystallized under similar
crystallization conditions with the same space group and
similar unit cell dimensions as the SCTWT (Table 1). Dif-
fraction data to 2.00 A˚ (SCTY84A) and 1.80 A˚ (dt-SCT)
were used for refinement of the final atomic models, which09–922, August 2007 ª2007 Elsevier Ltd All rights reserved 911
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SCTWT SCTY84A SCTY84C-PBL2C
Data Collection
Space group P21 P21 P21
Cell dimensions
a, b, c (A˚) 66.2, 89.6, 88.5 66.1, 89.3, 88.5 66.6, 89.1, 88.6
a = g = 90, b () 111.0 111.0 110.9
Number of molecules per ASU 2 2 2
Resolution (A˚) 20.0–2.00 (2.07–2.00)b 20–2.00 (2.07–2.0) 20–1.80 (1.86–1.80)
Rsym
a 7.5 (47.3) 9.3 (53.5) 5.8 (53.3)
I/sI 23.4 (3.80) 17.7 (3.07) 30.3 (3.39)
Completeness (%) 98.4 (97.2) 99.9 (99.7) 99.9 (100)
Redundancy 6.8 6.3 6.8
Refinement
Resolution (A˚) 20.0–2.00 (2.07–2.00) 20.0–2.00 (2.07–2.00) 20.0–1.80 (1.86–1.80)
Number of reflections 64087 (5963) 64727 (6111) 89351 (8411)
Rwork/Rfree
c 21.5 (34.1)/25.3 (35.1) 21.0 (30.8)/25.2 (34.7) 20.8 (33.3)/23.9 (34.2)
Number of atoms
Protein 6396 6382 6388
Water 639 700 755
B factors (A˚2)
Protein 35.8 30.2 34.9
Water 44.4 39.8 45.2
Rmsd from ideal values
Bond lengths (A˚) 0.0088 0.0086 0.0093
Bond angles () 1.56 1.55 1.678
Structural Comparisonsd
Rmsd (A˚) from 1VAC(c2)
Kb-Ova/HC/a1a2/b2m/Ova 1.96/1.15/0.61/0.98/0.52 2.15/1.34/0.78/0.83/0.48 2.15/1.37/0.81/0.97/0.51
Rmsd (A˚) from 1T0M(p21)
Kb/HC/a1a2/b2m 0.79/0.72/0.55/0.85 0.64/0.68/0.46/0.45 0.72/0.66/0.55/0.82
a Statistics as defined in SCALEPACK.
b Values in parentheses are for data in the highest resolution shell.
c Statistics as defined in CNS.
d Rmsd values calculated based on an alignment of main-chain atoms of the indicated complexes or domains using Lsqkab in
CCP4.have R factors of 21.0% (Rfree 25.2%) for SCT
Y84A and
20.8% (Rfree 23.9%) for dt-SCT. The electron density
maps for each of the SCT molecules were of excellent
quality (Figure 1C). Interpretable density was seen for res-
idues 1 through 7 and 11 through 15 in the first linker of
SCTY84A, and residues 1 through 7 and 12 through 15 in
the first linker of the dt-SCT. Furthermore, the electron
density in the F pocket of dt-SCT verifies the formation
of the engineered disulfide bond, which we designed to
enable durable peptide anchoring (Figure 1C). No inter-
pretable electron density was seen for the b2m-HC linker912 Chemistry & Biology 14, 909–922, August 2007 ª2007 Elsand for residues 278 through 280 at the C terminus of
the HC in any of the SCT structures.
To see how the peptide-b2m linker is accommodated in
the new SCT constructs and to assess the structural
changes in each MHC groove, we calculated the solvent
accessible surface [35] of the a1a2 domain in each SCT
by using a probe radius of 1.4 A˚ (Figure 2). Comparison
with the solvent accessible surface of native Kb reveals
the way in which Tyr84 closes the C-terminal end of the
Kb groove (Figure 2A). In contrast to SCTWT (Figure 2B),
the structures of SCTY84A and dt-SCT (Figures 2C andevier Ltd All rights reserved
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The solvent-accessible surfaces of the peptide-binding grooves of Kb (A), SCTWT (B), SCTY84A (C), and dt-SCT (D) are displayed as blue dotted sur-
faces. Ova, as well as the Ova portion and the first nine PBL residues in SCTWT, or the first six PBL residues in SCTY84A and the dt-SCT are represented
as CPK models and colored as in Figure 1B. Tyr84, as well as Ala84, and Cys84 are also depicted as CPK models and colored in light blue. Kb pocket
locations are indicated underneath each surface. For clarity, PBL residues are labeled L1 through L9 for SCTWT and L1 through L6 for SCTY84A and
dt-SCT.2D, respectively) have a novel channel that accommo-
dates the extrusion of the peptide-b2m linker away from
the TCR-proximal surface of the a1 helix. Thus, the groove
opening by the Y84A and Y84C mutations not only opti-
mized peptide-MHC interactions but also minimized the
possibility that linker residues would hinder immune rec-
ognition of antigen.
Structural and Functional Equivalence
between SCT and Native pMHC
Structural alignment of all of the single-chain platform do-
mains to native Kb bound to Ova yielded pair-wise all-
atom rmsd values of 1.14 A˚ for SCTWT, 1.32 A˚ for SCTY84A,
and 1.32 A˚ for dt-SCT, indicating that only minimal struc-
tural perturbations of the antigen presenting platform are
created in each SCT (Figure 3A). Most of the main-chain
differences were found in solvent-exposed, flexible loops
and the C-terminal regions of the a1a2 domains. Impor-
tantly, wild-type Kb-Ova crystallized with different lattice
contacts from the SCTs and comparisons of our struc-
tures with Kb and Kbm8 complexes with similar lattice inter-
actions indicated even smaller differences (Table 1).
These initial comparisons led us to believe that the engi-
neered perturbations in each SCT would have negligible
effects on T cell recognition. To test this hypothesis, the
SCT constructs were introduced into the LM1.8 cell line
and tested as targets in a chromium-release assay against
Kb-Ova reactive OT-1 T cells (Figure 3B). As we anticipated,
the OT-1 T cell clone recognized each SCT efficiently inChemistry & Biology 14, 90contrast to control LM1.8 Kb-transfected cells. This indi-
cated that each SCT construct folded properly in the ER
was expressed at the cell surface and retained the native
antigen recognition elements involved in TCR activation.
We also compared the conformations of Ova in each of
the SCT constructs to that of Ova in the native complex.
Alignment of the antigen-binding platforms revealed only
minor differences in the main-chain and side-chain atomic
positions for the anchoring Ova residues in each SCT
compared to Kb-Ova (Figures 3C and 3D). Likewise, the
conformations of solvent exposed Ova residues are also
very similar with the most significant differences seen for
the side chain of LysP7 (Figures 3C and 3D). Thus, our
SCT proteins can capably present peptides in a manner
very similar to their native counterparts.
Reconfiguration of F-Pocket Peptide Anchoring
Since the SCT format could impact anchoring of the C ter-
minus of the peptide, we analyzed the hydrogen bonding
established in the F pockets of each SCT (Figure 4) and
compared them to that in native Kb-Ova (Figure 4A). In
each structure, the amide nitrogen atom of GlyPBL1 oc-
cupies nearly the same position as one of the terminal
oxygen atoms of native Ova. A structurally conserved wa-
ter molecule, which mediates a number of important hy-
drogen bonds between the peptide C terminus and con-
served MHC residues, is present in all SCT structures
and is coordinated similarly as in the native structure. On
the other hand, Lys146, which normally hydrogen bonds9–922, August 2007 ª2007 Elsevier Ltd All rights reserved 913
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(A) The peptide-binding platforms of SCTWT (gray), SCTY84A (yellow), and dt-SCT (magenta) are superposed onto the platform of native Kb-Ova (cyan).
The superposition is based on the overlap of the main chain atoms of HC residues 1 through 182. The superposed structures are depicted as ribbon
tubes. Side chains for Ova residues in each SCT and in the native complex are rendered as ball-and-stick models and colored correspondingly.
(B) Response of OT-1 T cells to LM1.8 cells transfected with Kb and fed 10 mM Ova (panel 1, cyan) or transfected with SCTWT (panel 2, gray), SCTY84A
(panel 3, yellow), and dt-SCT (panel 4, magenta) is compared to the OT-1 response to control LM1.8 transfectants (H2-Kb, no peptide, shown in red in
each panel) in a 51Cr release assay. Error bars represent one standard deviation of three independent measurements.
(C and D) The Ova atomic positions in each SCT are compared to the native peptide. A close-up view of the superposed Ova peptides is shown at
a near 90 rotation from the orientation in (A). Aligned underneath the peptides (D) are quantified positional differences, which were graphed to denote
per residue main-chain (top) and side-chain (bottom) differences in reference to native Ova.to Tyr84 and the other terminal oxygen atom of Ova,
adopts one of two conformations in the different SCT
structures. In the SCTWT (Figure 4B) and SCTY84A
(Figure 4C) structures, Lys146 forms a hydrogen bond
with the carbonyl oxygen atom of LysP7, while in dt-SCT
(Figure 4D), it hydrogen bonds to the carbonyl oxygen of
GlyPBL1. A second water molecule is also located in the
F pocket of dt-SCT (Figure 4D), which is coordinated by
the amide nitrogen atom of CysPBL2 and the Od1 oxygen
atom of Thr80. Thus, the SCTY84A and the dt-SCT seem
to establish unique F-pocket hydrogen-bonding networks
compared to the native Kb-Ova complex; however, as
noted above, there are no major conformational differ-
ences between each SCT generation and the native com-
plex associated with the MHC groove re-engineering.914 Chemistry & Biology 14, 909–922, August 2007 ª2007 ElseStability of dt-SCT over SCTWT and SCTY84A
An important goal of expressing class I pMHC as SCT
was to achieve a kinetically stable assembly that retains
and presents a single peptide determinant. To test the
ability of the disulfide trap to secure the Ova sequence
in the dt-SCT protein, we used a highly sensitive T cell hy-
bridoma expressing the N15 TCR to detect exogenous
VSV8 peptide binding to Kb SCT constructs expressed
on LM1.8 cells (Figure 5A). We compared the relative ac-
cessibility of exogenous peptide binding to the various
Kb constructs by determining the concentration of VSV8
peptide required to achieve half-maximal activation of
the N15 hybridoma (Figure 5A). Our finding show that
SCTWT and SCTY84A proteins were greater than 1,000-
fold more resistant to exogenous peptide bindingvier Ltd All rights reserved
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Engineering of pMHC ReagentsFigure 4. Re-Engineering of F Pocket
Peptide Anchoring
HC residues involved in hydrogen bonding to
the main chain of LysP7 and LeuP8 in Kb-Ova
(A); LysP7, LeuP8, GlyPBL1, and GlyPBL2 in
SCTWT (B) and SCTY84A (C); and LysP7, LeuP8,
GlyPBL1, and CysPBL2 in dt-SCT (D) are shown
and colored in purple. Peptide and linker are
represented as in Figure 1B with side chains
beyond Cb atom omitted. Preserved hydrogen
bonds are shown as small silver balls, while
novel ones are depicted in green. Preserved
water molecules are colored in gray, while the
additional water molecule in dt-SCT is colored
in green. The main-chain traces of the peptide-
binding platforms are shown as thin cyan
tubes. The complex is oriented as in Figure 2B.
For clarity, PBL residues are labeled L1
through L7.compared with native Kb, confirming published findings
[29]. Most impressively, the novel disulfide trap makes
the SCT at least 100-fold more refractory than the previ-
ous SCT constructs and greater than 105 times more re-
sistant to exogenous peptide binding than native Kb.
We also tested the thermostability of purified, recombi-
nant SCTs by following their denaturation profiles as
a function of temperature by using CD spectroscopy. As
a control, we looked at the far UV spectra of the SCT pro-
teins at the beginning of each temperature denaturation
(10C), which show that each construct adopts similar
secondary structure in the solution conditions used in
these experiments (Figure 5B). Reproducibly higher Tm
values were observed for the dt-SCT protein (49.55C)
when compared with those of SCTWT and SCTY84A
(44.16C and 44.50C, respectively). This Tm increase is
comparable to that observed when a better anchoring res-
idue was introduced in a peptide bound to Kbm8 [36].
These thermostability data (Figure 5C) along with the pep-
tide competition analysis (Figure 5A) demonstrate that the
dt-SCT forms a stable assembly in which the disulfide trap
effectively prevents peptide dissociation. Furthermore, we
have also found that when relatively low affinity peptide
complexes with a different MHC allele (Ld) were com-
pared, the disulfide trap improved peptide occupancy rel-
ative to the native complex [37].
Characterization of SCT-Based Staining Reagents
We and others have recently shown that tetramers can be
constructed by using SCTs, and they reliably stain clonal T
cell populations [29, 38, 39]. To determine whether the
SCT engage its cognate TCR in a manner indistinguish-
able from the native pMHC, we performed competitive
staining of the same T cell sample with tetramers madeChemistry & Biology 14, 90of SCT or native Kb-Ova but conjugated to different fluoro-
chromes. When tested individually the tetramers con-
structed with SCTWT- or SCTY84A-stained OT-1 cells com-
parably to each other and to conventional tetramers
(Figure 6A and data not shown). More importantly, the
staining of SCT tetramers displayed a striking correlation
to the staining of conventional tetramers when tested in
combination demonstrating that SCT tetramers retained
specificity for the OT-1 TCR (Figure 6A).
We next determined whether polyclonal T cells re-
sponding to the native class I complex recognize equiva-
lently SCT-based tetramers. Six B6 mice were infected
with a strain of Listeria monocytogenes that expresses
ovalbumin. To determine the extent of overlap in CD8 T
cell populations that recognize each type of pMHC, tetra-
mers of both conventional and SCT configurations were
used to stain splenocytes from the infected mice
(Figure 6B). These studies revealed that similar numbers
of CD8 T cells were detected by each tetramer alone
(Figure 6B). More significantly, when conventional and
SCT tetramers linked to different fluorochromes were
used to simultaneously stain the B6 splenocytes, the
same polyclonal subset of antigen-specific T cells bound
equivalently to both tetramers (Figure 6B and Table S1,
see the Supplemental Data available with this article on-
line). Similar results were obtained after infection of B6
mice with gammaherpesvirus 68 expressing ovalbumin
(gHV68-Ova, data not shown). Neither conventional nor
SCT tetramers stained cells from uninfected B6 mice
(Figure S1A); negative control H2-Kb tetramers with an
irrelevant peptide (SIYRYYGL) did not stain OT-1,
uninfected B6, or pathogen-infected B6 splenocytes
(Figure S1B). Thus, these findings demonstrate that SCT
proteins have a native structure capable of specifically9–922, August 2007 ª2007 Elsevier Ltd All rights reserved 915
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finding further validates the use of SCT-based vaccines to
elicit physiologic immunity.
Figure 5. SCT Protein Stability and Prevention of Peptide
Exchange
(A) N15 hybridoma activation to detect VSV8 binding to native Kb or
SCT proteins. LM1.8 cells expressing the indicated constructs were in-
cubated for 24 hr with increasing concentration of exogenous VSV8
peptide. IL-2 production was measured via proliferation of CTL L-2
cells, which was in turn detected by Alamar blue fluorescence at
590 nm. Horizontal gray line shows the level of half-maximal hybrid-
oma activation.
(B) Far UV CD spectra of SCTWT, SCTY84A, dt-SCT, and Kb-Ova. The
measured CD signal is given as [Molar Ellipticity]r, the molar ellipticity
per residue.
(C) Thermostability as measured by CD. Increase in the CD signal at
220 nm as a function of temperature was normalized to a scale of 0
to 100. The Tm (see Experimental Procedures) for each protein is
denoted in the legend.916 Chemistry & Biology 14, 909–922, August 2007 ª2007 ElsGeneration of Disulfide-Trapped pMHC Reagents
We next considered the possibility of generating pMHC
tetramers in which only the peptide is permanently at-
tached to the class I HC. We reasoned that covalent at-
tachment of synthetic peptide through a disulfide bond
would preclude the need for stabilizing linkers involving
b2m. The result would be a minimally modified class I
pMHC with a synthetic peptide disulfide-trapped to the
peptide-binding groove. We designated these recombi-
nant molecules disulfide-trap pMHC, or dt-pMHC.
To generate these complexes, soluble Kb HC carrying
the Y84C mutation and C-terminal biotinylation sequence
[40] was refolded with b2m and a modified Ova peptide.
This peptide was C-terminally extended to include a Gly-
Cys sequence for disulfide bond formation analogous to
the one observed in the dt-SCT structure. To demonstrate
conclusively that tetramers of the dt-pMHC format are
valid reagents that mimic exactly the native MHC class I
determinant, we used the system described above to per-
form dual tetramer staining. OT-1 staining by both tetra-
mers either alone or in combination clearly verified that
this TCR is detected equivalently by disulfide-trapped
and conventional tetramers (Figure 6A). Likewise, each
tetramer stained similar numbers of CD8 T cells from six
individual L.m.-Ova infected mice, and when staining si-
multaneously with both tetramers, the antigen-specific
CD8 T cells were bound by both tetramers (Figure 6B
and Table S1). Furthermore, tetramer staining of spleno-
cytes from B6 mice infected with gHV68-Ova yielded
very similar patterns (data not shown). These results dem-
onstrate that disulfide-trap technology can be used to co-
valently attach a synthetic peptide antigen to a recombi-
nant MHC HC. Our data furthermore demonstrate that
this novel approach will make staining reagents with the
specificity and sensitivity to enumerate polyclonal CD8 T
cells. As discussed below, construction of disulfide-trap
tetramers should be universally applicable and offers
a promising, alternative approach to make straining reagents
to pathogen-derived epitopes in situations where conven-
tional tetramers are unstable or short lived.
DISCUSSION
In order to develop novel MHC I-based reagents for vac-
cines and probes for pathogen surveillance, we engi-
neered three consecutive SCT designs that are character-
ized here biophysically and functionally. Our studies show
that the progressive SCT generations manifest dramatic
improvements in linker accommodation, C-terminal pep-
tide anchoring, and improved resistance to exogenous
peptide exchange. Although the data presented here is
based on the well-defined Kb-Ova model system, our ap-
proaches are completely general and will readily extend to
other mouse and human class I alleles. To date, we and
others have reported first-generation SCT constructs
with human HLA-A2, -B27, and -E as well as murine H2-
Kb, -Ld, and -Db each bound by different peptide ligands
[38, 39, 41]. Furthermore, we expect that the novel disul-
fide trap technology characterized here will also extendevier Ltd All rights reserved
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tion of our engineering with the highly conserved chemical
basis of class I C-terminal peptide anchoring. In particular,
since Tyr84 is invariant in all mouse and human class I al-
leles, we anticipate that our disulfide-trap positioning
can be readily employed to generate analogous trapped
pMHC from other class I alleles as well. In strong support
of the general applicability, we have incorporated an anal-
ogous trap in two complexes known to contain relatively
poor binding peptides—mouse H2-Ld bound by the QL9
peptide involved in allorecognition and human HLA-A2
bound by the G280 peptide involved in melanoma detec-
tion [37].
Our structural data shows that the Y84C mutation re-
structures the Kb groove to open a channel allowing the
linker to freely extrude from the peptide-binding platform.
In addition, experimental electron density maps for the dt-
SCT protein unambiguously show the presence of a disul-
fide bond between CysPBL2 and Cys84. We also present
experimental evidence that the presence of this disulfide
bridge increases the thermal stability of the SCT format
and effectively prevents binding of competitor peptides.
Consequently, incorporation of disulfide traps will have
great potential for broadening the application of SCTs to
include physiologically important antigenic peptides that
are not tight binders.
Recently, four studies on the use of first generation SCT
in DNA vaccinations for cancer prevention have been re-
ported. In one of these studies, a DNA construct encoding
a breast cancer epitope derived from mammoglobin-A
presented in the context of HLA-A2 as a SCT was used
successfully in vaccination of mice to induce the specific
expansion of epitope-positive CTLs [42]. In the second
study, mice vaccinated with SCT proteins presenting an
immunodominant epitope derived from HPV-16 E6 protein
in the context of H2-Kb exhibited significantly increased
E6 peptide-specific responses compared to mice immu-
nized with DNA encoding E6 protein. Moreover, 100% of
the mice vaccinated with the SCT encoding DNA were
protected against lethal challenge with E6-expressing tu-
mors [43]. Using a similar approach, SCT-based vaccines
were very recently found to be efficacious against human
ovarian cancer [44]. Finally, a single-chain trimer of HLA-
A2 linked to human mesothelin peptide was shown to
generate an antitumor effect against human mesothelin-
expressing tumors [45]. Based on the findings reported
here, it is highly likely that the SCTs incorporating disulfide
traps could offer further advantages due to their improved
stability and resistance to exogenous peptide exchange.
Our findings with the SCT disulfide trap and its ability to
improve F-pocket anchoring suggested that the linkers in-
volving b2m might be eliminated to make tetramers with
only a disulfide-trapped peptide. More specifically, we
tested whether an E. coli produced, soluble HC with
a Y84C mutation could be refolded in the presence of
a synthetic peptide with a GC extension. As reported
here, this approach worked beautifully to produce disul-
fide-trap Kb-Ova tetramers, and these dt-pMHC tetramers
clearly stained pathogen-induced polyclonal a-Kb-OvaChemistry & Biology 14, 90T cells with the same specificity as conventional wild-
type tetramers.
Recombinant dt-pMHC molecules feature a significant
advantage over their single-chain counterparts. Bacterial
production of SCT is dependent on successful N-formyl
methionine (fMet) cleavage to reveal the N-terminus for
the correct SCT incorporated peptide sequence. How-
ever, this cleavage event depends on the amino acid
size following the initiator fMet [46, 47]. Therefore, bacte-
rial expression of SCT proteins is limited to those that have
antigenic peptide sequences, such as Ova, that allow for
efficient fMet cleavage. Due to these sequence limitations,
it is clear that the most efficient way to introduce the engi-
neered disulfide bond into recombinant pMHC is the
dt-pMHC approach introduced and validated in this study.
SIGNIFICANCE
Herein, we present the structural and functional char-
acterization of three generations ofMHC I proteins de-
signed as single-chain trimers.We connected peptide,
b2m, and HCwith flexible linkers into a single polypep-
tide. This initial design was improved by reengineering
the MHC groove to accommodate the peptide-b2m
linker and by disulfide trapping to enhance peptide-
MHC association. Importantly, these improvements
were made without any structural or functional com-
promises, as assessed by crystallography, highly sen-
sitive T cells activation assays, and flow cytometry of
pathogen-specific monoclonal and polyclonal T cells.
Due to their preassembled nature, SCT proteins by-
pass conventional antigen processing, express effi-
ciently at the cell surface [26, 29, 37], and potently
stimulate CD8 T cells in vivo [48, 49]. These properties
afford us a unique opportunity to broaden the produc-
tion of antigen-specific DNA vaccines to include the
induction of subdominant immune responses that in
many cases are critically important in producing
a broadly effective immunity against tumors [45, 50,
51] and pathogens [49, 52–54]. Likewise, the novel
coupling of peptide and class I HC using our method
of covalent disulfidebond trapping represents a versa-
tile approach for generating soluble covalently linked
pMHC reagents. In the case of MHC complexes that
involve weak-binding peptides, such reagents may
have dramatically improved shelf life and quality of
staining. Thus, our disulfide-trap SCT and soluble
pMHC reagents have exciting application for the
diagnosis and modulation of T cell responses to path-
ogens and tumors.
EXPERIMENTAL PROCEDURES
Protein Expression and Purification
Each SCT (Figure 1A) was expressed in the bacterial strain BL21Co-
donPlus(DE3)RIL (Stratagene, La Jolla, CA), and insoluble inclusion
bodies were prepared as previously described [55]. To form the SCT
proteins, inclusion bodies were solubilized in 6 M GdnHCl, 10 mM
Tris (pH 8.0), and 10 mM b-mercaptoethanol and refolded under oxida-
tive conditions at 4C by a rapid dilution method as described9–922, August 2007 ª2007 Elsevier Ltd All rights reserved 917
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spaced over an 8 hr period into 500 ml of refolding buffer. After an over-
night incubation, the refolding reaction was concentrated to 4 ml and
the formed SCT proteins were purified by size-exclusion and anion-
exchange chromatographies as previously described [55]. Prior to
crystallization, the purified SCT proteins were exchanged in buffer
containing 20 mM HEPES (pH 7.5) and 20 mM NaCl. Electrospray
mass spectral analysis of each SCT confirmed the presence of abun-
dant peaks at 47,003 Da, 46,909 Da, and 46,985 Da, respectively cor-
responding to the predicted molecular weights of SCTWT, SCTY84A,
and properly oxidized dt-SCT.
Crystallization and Data Collection
Crystals of each SCT were obtained by hanging-drop, vapor-diffusion
method. Protein at 6 to 8 mg/ml was equilibrated at 20C against 13%
(w:v) polyethylene glycol (PEG) 10,000 and 100 mM MES (pH 6.2) for
SCTWT, 14% PEG 6,000 and 100 mM MES (pH 6.4) for SCTY84A, and
13% PEG 6,000 and 100 mM MES (pH 6.3) for dt-SCT. Small crystals
obtained in these drops were used to microseed protein hanging drops
equilibrated against similar conditions with marginally lower concen-
trations of PEG. Prior to data collection, crystals were soaked in crys-
tallization buffer to which ethylene glycol was added to a final concen-
tration of 20% (v:v) as cryoprotectant. X-ray diffraction data were
collected on the ID-19 beamline at APS. Three hundred and sixty
frames were collected for each crystal; each frame representing
a 1.0 oscillation range. These data were indexed and integrated
with DENZO (HKL Suite, HKL Research, Inc., Charlottesville, VA) and
scaled and merged with SCALEPACK (HKL Suite, HKL Research,
Inc., Charlottesville, VA) (Table 1). Wilson scaling was applied to the
final output structure factor amplitudes (Collaborative Computing Pro-
ject 4 [CCP4], Daresbury Laboratory, Warrington, UK [56]).
Structure Determination and Refinement
Initial phases for each structure were obtained by rigid-body refine-
ment of the coordinates of H2-Kbm8 (PDB code: 1RJY) against each
of the data sets. Extensive model building was performed with the
modeling program O (O version 6.22, Uppsala Software Factory, Swe-
den) with 2FO-FC, FO-FC, and 2FO-FC composite omit maps (CNS, Yale
University, New Haven CT [57]). Atomic refinement was done employ-
ing simulated annealing, energy minimization, and restrained B-factor
refinement protocols as implemented in CNS and CCP4.
Computational Analysis
Graphical representations were primarily created by using Ribbons
[58]. Molecular surfaces of the peptide-binding grooves were gener-
ated with InsightII (Biosym Technologies, San Diego, CA). Superposi-
tions and rmsd calculations were obtained with Lsqkab (CCP4). Rmsd
values between the aligned peptides were calculated using CNS [57].
HBPLUS [59] was used to catalog contacting atoms and putative
hydrogen bonds.
T Cell Assays
OT-1 T cells were assayed in a 4 hr 51Cr release assays as previously
described [26]. Target cells for these assays were LM1.8-Kb cells [29]
incubated with or without 10 mM exogenous peptide or LM1.8 cells
transduced with SCT constructs by using a pMSCV-based retroviral
vector (Clontech, Mountain View, CA) and the Vpack retroviral expres-
sion system (Stratagene). Kb-VSV8 reactive N15 hybridoma cells [60]
were a gift of Dr. Hsiu-Ching, Dana-Farber Cancer Institute, HarvardChemistry & Biology 14, 90Medical School. For peptide competition assays, LM1.8 cells (2 3
104/200 ml/well) expressing native Kb or the SCT constructs were incu-
bated for 24 hr in a 96-well plate with N15 hybridoma cells (23 105/200
ml/well) in the continuous presence of the indicated concentrations of
VSV8 peptide. Relative amounts of IL2 secretion were measured by
proliferation of CTLL-2 cells as quantified with Almar blue (BioSource
Int., Camarillo, CA).
Thermal Denaturation Studies
Purified SCT proteins and Kb-Ova were dialyzed against buffer con-
taining 10 mM K2HPO4/KHPO4 (pH 7.5) and 150 mM NaCl. The pro-
teins were diluted to 475 nM in buffer containing 20 mM K2HPO4/
KHPO4 (pH 7.5) and 150 mM NaCl. CD spectra at 10
C were collected
between 260 and 200 nm at 0.5 nm increments on Jasco-810 instru-
ment (Jasco Inc., Easton, MD) equipped with Peltier temperature con-
troller. The thermal denaturation profiles were monitored by the
change in CD signal at 220 nm as a function of temperature. Thermal
scan data were collected at a 1.0C interval from 10C to 70C with
a temperature ramp rate of 50C/hour. Thermal denaturation curves
were scaled from 0% to 100% to provide plots of the percent of signal
change versus temperature. The Tm is the temperature at which the CD
signal change is half of the total signal change. All measurements were
made at least four times and averaged; standard deviations of each
measurement were also calculated and presented.
Tetramer Construction
Peptides were obtained commercially or synthesized on an Applied
Biosystems Model 432A peptide synthesizer. H2-Kb-Ova (SIINFEKL)
and negative control H2-Kb-SIYR (SIYRYYGL) tetramers were con-
structed according to conventional methods [61]. SCTY84A tetramers
were prepared in a similar manner, as described previously [29]. The
construction of disulfide-trapped (dt-pMHC) tetramers was accom-
plished by refolding synthetic SIINFEKLGC peptide with b2m and
H2-Kb HC with the mutation Y84C. The dt-pMHC tetramers and con-
trols included the mutation C121S to remove the unpaired cysteine
from Kb. Molecular weights of each recombinant MHC were confirmed
by mass spectrometry. For tetramerization, phycoerythrin-(PE-) or al-
lophycocyanin-(APC-)streptavidin (BD Biosciences, San Jose, CA)
was added at a molar ratio of one fluorochrome-conjugated streptavi-
din to four biotinylated MHC. The stock concentration of all tetramer
preparations was 4.3 ± 0.2 mM MHC monomer, and tetramer staining
was calibrated on OT-1 transgenic T cells to obtain matching fluores-
cence intensity for tetramers with different fluorochromes.
Listeria Infections and Tetramer Staining
B6 mice were infected by tail vein injection with 5 3 103 cfu of Listeria
monocytogenes expressing ovalbumin (L.m.-Ova, a kind gift of Hao
Shen, University of Pennsylvania) in 200 ml saline. After 7 days, spleno-
cytes were stained with tetramers and FITC-conjugated anti-CD8 (BD
Biosciences). Uninfected OT-1 splenocytes were stained in the same
manner. All plots are gated on CD8 cells, and dead cells were excluded
by propidium iodide staining. A FACSCalibur instrument and CELL-
Quest software (BD Biosciences) were used for data acquisition and
analysis. Greater than 15,000 CD8+ events were collected per staining
in order to reliably determine the frequency of tetramer-positive CD8 T
cells. Percentages of tetramer-positive CD8 T cells for six L.m.-Ova in-
fected B6 mice are listed in Table S1. Negative control tetramers
stained less than 0.8% of CD8 T cells (Figure S1). Representative
data are shown for one of the six B6 mice.Figure 6. Application of Disulfide-Trap Technology for Soluble Reagent Generation
Flow cytometry was used to detect staining of CD8+ lymphocytes by conventional and engineered pMHC tetramers. All plots are gated on CD8+ cells,
and percentages of CD8+ cells are given for relevant quadrants. (A) OT-1 transgenic splenocytes were stained individually (first row) with conventional
Kb-Ova tetramers conjugated to APC (left panel), SCTY84A tetramers conjugated to PE (middle panel), or Kb-Ova-based dt-pMHC tetramers conju-
gated to PE (right panel). These cells were then double stained (second row) with conventional Kb-Ova and SCTY84A tetramers (left panel) or Kb-Ova
and dt-pMHC tetramers (right panel). (B) H2-Kb-Ova-specific polyclonal T cells were generated by infecting B6 mice intravenously with 53 103 cfu of
L.m.-Ova. After 7 days, splenocytes were harvested and stained as described in (A).9–922, August 2007 ª2007 Elsevier Ltd All rights reserved 919
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Supplemental Data demonstrate the specificity of tetramer staining
and are available at http://www.chembiol.com/cgi/content/full/14/8/
909/DC1/.
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